4.7 Review

Key quality factors for Chinese herbal medicines entering the EU market

Journal

CHINESE MEDICINE
Volume 17, Issue 1, Pages -

Publisher

BMC
DOI: 10.1186/s13020-022-00583-x

Keywords

Chinese herbal medicines; European Pharmacopoeia; Chinese Pharmacopoeia; Quality requirements; European herbal medicine legislation; European market

Funding

  1. Science and Technology Development Fund, Macau SAR [0016/2021/A]
  2. National Natural Science Foundation of China [82104354]
  3. University of Macau [MYRG2018-00207-ICMS, MYRG2019-00121-ICMS]
  4. Guangxi Science and Technology Research Project [GuiKe AA18242040]
  5. Dutch Provincie Noord_Holland MIT grant [1275358/1326082]

Ask authors/readers for more resources

This article mainly discusses the quality requirements and regulations for Chinese herbal medicines to enter the European Union market. By comparing the quality control and registration routes of herbal medicines in China and Europe, it provides a reference for the development of Chinese herbal medicines in the EU market.
Chinese herbal medicines (CHMs) have unique advantages in the prevention and treatment of diseases, which are widely recognized in the world. More and more CHMs are becoming increasingly popular in the international markets. However, the quality control of CHMs is a significant issue for their acceptance and recognition in the international market. This review mainly focuses on the quality requirements for CHMs to enter the European Union (EU) market. Both Chinese and European regulations and quality controls are compared. Firstly, the EU medicinal regulatory system and relevant regulations were reviewed. Secondly, the key factors of the quality control of CHMs, including Chinese herbal drugs, extracts and products were compared with those of European herbal medicines in the EU market. Subsequently, three main registration routes for herbal medicinal products including Chinese herbal medicinal products entering the EU were introduced. Furthermore, the legal status of traditional Chinese medicine granules in the EU was also discussed. Through the comparison of the key quality factors for CHMs in China and the EU, the similarities and differences in terms of quality requirements and regulations are addressed, which provides a reference for the development of CHMs into the EU market.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available